<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656249</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-JS-1391</org_study_id>
    <nct_id>NCT04656249</nct_id>
  </id_info>
  <brief_title>Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer</brief_title>
  <acronym>LENABC</acronym>
  <official_title>The Efficacy and Safety of Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, nonrandom, open-label study aiming to evluate the efficacy and&#xD;
      safety of lenvatinib for patients with pretreated advanced biliary tract cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lenvatinib targets VEGFR1, 2, and 3, PDGFRα, Fibroblast growth factor receptor (FGFR), and&#xD;
      the KIT and RET tyrosine kinases and was initially developed for use in various tumor types.&#xD;
      This is a single-center, non-random, open-label study in participants with unresectable BTC&#xD;
      and disease progression or failure following at least one chemotherapy regimen. This study&#xD;
      contains three procedures: a pre-treatment procedure that will last within 21 days; a&#xD;
      treatment procedure that will consist of study treatment cycles and tumor assessment&#xD;
      conducted every 6-8 weeks; and a follow-up procedure that will begin immediately after the&#xD;
      off-treatment visit and will continue as long as the participant is alive, unless the&#xD;
      participant withdraws consent, or until the terminal of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">May 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients are confirmed with biliary tract cancers by imaging and histological examination and meet with the inclusive criteria, including intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, common bile duct cancer and gallbladder cancer.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Six months</time_frame>
    <description>Objective response rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Six months</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Two years</time_frame>
    <description>Overall survival (OS) [ Time Frame: From the date of first dose of study drug to the date of death from any cause, or up to approximately 2 years ]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Six months</time_frame>
    <description>DCR is defined as the percentage of participants with complete response (CR) + partial response (PR) + stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rate of Treatment Related Adverse Events</measure>
    <time_frame>Three years</time_frame>
    <description>Treatment related adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE 4.0). The study recorded the occurrence rate of treatment related AEs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>One years</time_frame>
    <description>Clinical benefit rate (CBR) [ Time Frame: From the date of first dose of study drug to the date of the first documentation of disease progression or death from any cause, whichever occurs first, or up to approximately 1 years ]</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <condition>Biliary Tract Cancer</condition>
  <condition>Targeted Therapy</condition>
  <arm_group>
    <arm_group_label>Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing &lt;60 kg and 12mg/d to those ≥60 kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing &lt;60 kg and 12mg/d to those ≥60 kg.</description>
    <arm_group_label>Lenvatinib</arm_group_label>
    <other_name>E7080</other_name>
    <other_name>Lenvima</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria:&#xD;
&#xD;
               1. Pathologically or cytologically confirmed adenocarcinoma of biliary tract cancer&#xD;
                  (intrahepatic, extrahepatic cholangiocarcinoma, gall bladder cancer), at least&#xD;
                  one prior chemotherapy.&#xD;
&#xD;
               2. Participants who received adjuvant chemotherapy are eligible if this therapy was&#xD;
                  completed and recurrent has not been shown for 6 months after the completion of&#xD;
                  the therapy&#xD;
&#xD;
               3. Measurable disease meeting the following criteria: At least 1 lesion of ≥ 1.0 cm&#xD;
                  in the longest diameter for a non-lymph node or ≥ 1.5 cm in the short-axis&#xD;
                  diameter for a lymph node that is serially measurable according to Response&#xD;
                  Evaluation Criteria in Solid Tumors 1.1 (RECIST1.1) using computerized&#xD;
                  tomography/magnetic resonance imaging (CT/MRI). Lesions that have had external&#xD;
                  beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF)&#xD;
                  ablation must show evidence of progressive disease based on RECIST 1.1 to be&#xD;
                  deemed a target lesion.&#xD;
&#xD;
               4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1&#xD;
&#xD;
               5. Survival expectation of 3 months or longer after beginning of study treatment&#xD;
&#xD;
               6. Males or females age ≥ 18 years at the time of informed consent&#xD;
&#xD;
               7. All chemotherapy- or radiation-related toxicities must have resolved to Grade 0-1&#xD;
                  per Common Terminology Criteria for Adverse Events (CTCAE v 4.03), except&#xD;
                  alopecia, infertility, and the adverse events listed in inclusion criteria&#xD;
&#xD;
               8. Adequately controlled blood pressure (BP) with or without antihypertensive&#xD;
                  medications (defined as BP ≤ 150/90 mm Hg at Screening and no change in&#xD;
                  antihypertensive medications within 1 week prior to the first dose of study drug)&#xD;
&#xD;
               9. Participants with adequate function of major organs and blood coagulation:&#xD;
&#xD;
              10. Absolute neutrophil count (ANC) ≥ 1500/mm^3 ( ≥ 1.5×103/μl); Platelets ≥&#xD;
                  100,000/mm3 ( ≥ 100×10^9/L); Hemoglobin ≥ 9.0 g/dL; Bilirubin ≤ 2.0 mg/dL except&#xD;
                  for unconjugated hyperbilirubinemia or Gilbert's syndrome; Alkaline phosphatase&#xD;
                  (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤ 3.0&#xD;
                  × upper limit of normal (ULN) ( ≤ 5.0 × ULN for participants with the liver&#xD;
                  metastasis); Creatinine clearance ≥ 40 mL/min per the Cockcroft and Gault&#xD;
                  formula; Prothrombin time-International Normalized Ratio (PT-INR) ≤ 1.5;&#xD;
&#xD;
              11. Participants must voluntarily agree to provide written informed consent;&#xD;
&#xD;
              12. Participants must be willing and able to comply with all aspects of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ascites of moderate, severe, or requiring drainage&#xD;
&#xD;
          2. Proteinuria of ≥ 2+ on dipstick testing (Grade ≤ 1 confirmed by quantitative&#xD;
             assessment is eligible)&#xD;
&#xD;
          3. Gastrointestinal malabsorption or any other condition that in the opinion of the&#xD;
             investigator might affect the absorption of study drug&#xD;
&#xD;
          4. New York Heart Association congestive heart failure of class II or above, unstable&#xD;
             angina, myocardial infarction, or serious cardiac arrhythmia associated with&#xD;
             significant cardiovascular impairment within the past 6 months from the first dose of&#xD;
             study drug&#xD;
&#xD;
          5. A prolonged QT/QTc interval (QTcF &gt; 480 ms)&#xD;
&#xD;
          6. Known to be human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          7. Active infection requiring systemic treatment&#xD;
&#xD;
          8. Bleeding or thrombotic disorders or chronic systemic use of anticoagulants requiring&#xD;
             therapeutic INR monitoring, eg, warfarin or similar agents (treatment with low&#xD;
             molecular weight heparin is permitted)&#xD;
&#xD;
          9. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5&#xD;
             teaspoon) within 21 days prior to the first dose of study drug Active malignancy&#xD;
             (except for BTC or definitively treated melanoma in-situ, basal or squamous cell&#xD;
             carcinoma of the skin, carcinoma in-situ of the cervix, or early stage&#xD;
             gastric/colorectal cancer) within the past 24 months prior to the first dose of study&#xD;
             drug&#xD;
&#xD;
         10. Known intolerance to the study drug or any of the excipients&#xD;
&#xD;
         11. History of drug or alcohol dependency or abuse within the last 24 months prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
         12. Any medical or other condition that in the opinion of the investigator(s) would&#xD;
             preclude the participant's participation in a clinical study&#xD;
&#xD;
         13. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a&#xD;
             positive human chorionic gonadotropin [hCG or B-hCG]). A separate baseline assessment&#xD;
             is required if a negative screening pregnancy test was obtained more than 3 days&#xD;
             before the first dose of study drug.&#xD;
&#xD;
         14. For either males unless undergoing a successful vasectomy (confirmed azoospermia) or&#xD;
             females of childbearing potential, the participant and his/her partner do not agree to&#xD;
             use a medically appropriate method of contraception throughout the entire study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hai-Tao Zhao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences &amp; Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.</citation>
    <PMID>29433850</PMID>
  </results_reference>
  <results_reference>
    <citation>Marquardt JU, Saborowski A, Czauderna C, Vogel A. The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. Target Oncol. 2019 Apr;14(2):115-123. doi: 10.1007/s11523-019-00624-w. Review.</citation>
    <PMID>30805831</PMID>
  </results_reference>
  <results_reference>
    <citation>Obi S, Sato T, Sato S, Kanda M, Tokudome Y, Kojima Y, Suzuki Y, Hosoda K, Kawai T, Kondo Y, Isomura Y, Ohyama H, Nakagomi K, Ashizawa H, Miura Y, Amano H, Mochizuki H, Omata M. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatol Int. 2019 Mar;13(2):199-204. doi: 10.1007/s12072-019-09929-4. Epub 2019 Jan 22.</citation>
    <PMID>30671808</PMID>
  </results_reference>
  <results_reference>
    <citation>Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med. 2019 Jan;8(1):137-146. doi: 10.1002/cam4.1909. Epub 2018 Dec 21.</citation>
    <PMID>30575325</PMID>
  </results_reference>
  <results_reference>
    <citation>El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May;142(6):1264-1273.e1. doi: 10.1053/j.gastro.2011.12.061. Review.</citation>
    <PMID>22537432</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang B, Zhang B, Zhang Z, Huang Z, Chen Y, Chen M, Bie P, Peng B, Wu L, Wang Z, Li B, Fan J, Qin L, Chen P, Liu J, Tang Z, Niu J, Yin X, Li D, He S, Jiang B, Mao Y, Zhou W, Chen X. 42,573 cases of hepatectomy in China: a multicenter retrospective investigation. Sci China Life Sci. 2018 Jun;61(6):660-670. doi: 10.1007/s11427-017-9259-9. Epub 2018 Feb 2.</citation>
    <PMID>29417360</PMID>
  </results_reference>
  <results_reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </results_reference>
  <results_reference>
    <citation>Witjes CD, Karim-Kos HE, Visser O, de Vries E, IJzermans JN, de Man RA, Coebergh JW, Verhoef C. Intrahepatic cholangiocarcinoma in a low endemic area: rising incidence and improved survival. HPB (Oxford). 2012 Nov;14(11):777-81. doi: 10.1111/j.1477-2574.2012.00536.x. Epub 2012 Aug 17.</citation>
    <PMID>23043667</PMID>
  </results_reference>
  <results_reference>
    <citation>Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014 Jun;60(6):1268-89. doi: 10.1016/j.jhep.2014.01.021. Epub 2014 Mar 27.</citation>
    <PMID>24681130</PMID>
  </results_reference>
  <results_reference>
    <citation>Ueno M, Ikeda M, Sasaki T, Nagashima F, Mizuno N, Shimizu S, Ikezawa H, Hayata N, Nakajima R, Morizane C. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer. 2020 Nov 16;20(1):1105. doi: 10.1186/s12885-020-07365-4.</citation>
    <PMID>33198671</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, Han GH, Wang MQ, Liu RB, Lu LG, Ren ZG, Chen MS, Zeng ZC, Liang P, Liang CH, Chen M, Yan FH, Wang WP, Ji Y, Cheng WW, Dai CL, Jia WD, Li YM, Li YX, Liang J, Liu TS, Lv GY, Mao YL, Ren WX, Shi HC, Wang WT, Wang XY, Xing BC, Xu JM, Yang JY, Yang YF, Ye SL, Yin ZY, Zhang BH, Zhang SJ, Zhou WP, Zhu JY, Liu R, Shi YH, Xiao YS, Dai Z, Teng GJ, Cai JQ, Wang WL, Dong JH, Li Q, Shen F, Qin SK, Fan J. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer. 2018 Sep;7(3):235-260. doi: 10.1159/000488035. Epub 2018 Jun 14.</citation>
    <PMID>30319983</PMID>
  </results_reference>
  <results_reference>
    <citation>Ji X, Bu ZD, Yan Y, Li ZY, Wu AW, Zhang LH, Zhang J, Wu XJ, Zong XL, Li SX, Shan F, Jia ZY, Ji JF. The 8th edition of the American Joint Committee on Cancer tumor-node-metastasis staging system for gastric cancer is superior to the 7th edition: results from a Chinese mono-institutional study of 1663 patients. Gastric Cancer. 2018 Jul;21(4):643-652. doi: 10.1007/s10120-017-0779-5. Epub 2017 Nov 22.</citation>
    <PMID>29168120</PMID>
  </results_reference>
  <results_reference>
    <citation>Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: A Review in Hepatocellular Carcinoma. Drugs. 2019 Apr;79(6):665-674. doi: 10.1007/s40265-019-01116-x. Review.</citation>
    <PMID>30993651</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. Gut Liver. 2016 May 23;10(3):332-9. doi: 10.5009/gnl15257. Review.</citation>
    <PMID>27114433</PMID>
  </results_reference>
  <results_reference>
    <citation>Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, Petrelli F. Biliary tract cancer: current challenges and future prospects. Cancer Manag Res. 2018 Dec 28;11:379-388. doi: 10.2147/CMAR.S157156. eCollection 2019. Review.</citation>
    <PMID>30643463</PMID>
  </results_reference>
  <results_reference>
    <citation>Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O'Dwyer PJ, Sepulveda A, Sun W. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol. 2013 Dec;24(12):3061-5. doi: 10.1093/annonc/mdt416. Epub 2013 Oct 20.</citation>
    <PMID>24146220</PMID>
  </results_reference>
  <results_reference>
    <citation>Snyder A, Morrissey MP, Hellmann MD. Use of Circulating Tumor DNA for Cancer Immunotherapy. Clin Cancer Res. 2019 Dec 1;25(23):6909-6915. doi: 10.1158/1078-0432.CCR-18-2688. Epub 2019 Jul 8. Review.</citation>
    <PMID>31285372</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang D, Lin J, Yang X, Long J, Bai Y, Yang X, Mao Y, Sang X, Seery S, Zhao H. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol. 2019 Apr 24;12(1):42. doi: 10.1186/s13045-019-0730-9. Review.</citation>
    <PMID>31014381</PMID>
  </results_reference>
  <results_reference>
    <citation>Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 2017 Sep;7(9):943-962. doi: 10.1158/2159-8290.CD-17-0245. Epub 2017 Aug 17. Review.</citation>
    <PMID>28818953</PMID>
  </results_reference>
  <results_reference>
    <citation>Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D, Waterhouse D, Domine M, Garassino M, Chow LQM, Blumenschein G Jr, Barlesi F, Coudert B, Gainor J, Arrieta O, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Crinò L. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018 Apr 1;29(4):959-965. doi: 10.1093/annonc/mdy041.</citation>
    <PMID>29408986</PMID>
  </results_reference>
  <results_reference>
    <citation>Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, Matsui J. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018 Jun;7(6):2641-2653. doi: 10.1002/cam4.1517. Epub 2018 May 7.</citation>
    <PMID>29733511</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lenvatinib</keyword>
  <keyword>Refractory biliary tract carcinoma</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

